D-cycloserine Augmented Treatment for Youth With Tic Disorders

Status Withdrawn

Clinical Trial Summary

This pilot study aims evaluate the feasibility and initial efficacy of behavior therapy augmented by d-cycloserine (DCS) compared to behavior therapy augmented by placebo. After an initial assessment to determine eligibility, youth with TD will be randomly assigned to receive four sessions of behavior therapy augmented by either DCS or placebo. D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. The investigators' proof-of-concept work has found that a single session of DCS-augmented behavior therapy reduced the severity of tics targeted in treatment on the Hopkins Motor/Vocal Tic Scale (HM/VTS) compared to placebo-augmented behavior therapy. This highlights the exciting potential of combining DCS with behavior therapy to improve reductions in tic severity. However, prior to a large-scale clinical trial, it is essential to determine the feasibility and efficacy of augmenting behavior therapy with DCS over multiple treatment sessions.

Clinical Trial Description

Tourette's Disorder and Persistent Tic Disorders (collectively referred to as TD) are characterized by the presence of motor and/or vocal tics. For many youth with TD, the severity of tics results in considerable functional impairment and a poor quality of life. While historically managed with psychotropic medications, behavior therapy has demonstrated efficacy for reducing the severity of tics. However, only 50% of youth with TD exhibit a positive treatment response to behavior therapy, and many treatment responders continue to experience bothersome tics. Thus, there is a need to investigate strategies to improve therapeutic outcomes from behavior therapy for youth with TD. This pilot study aims evaluate the feasibility and initial efficacy of behavior therapy augmented by d-cycloserine (DCS) compared to behavior therapy augmented by placebo. After an initial assessment to determine eligibility, youth with TD will be randomly assigned to receive four sessions of behavior therapy augmented by either DCS or placebo. D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. The investigators' proof-of-concept work has found that a single session of DCS-augmented behavior therapy reduced the severity of tics targeted in treatment on the Hopkins Motor/Vocal Tic Scale (HM/VTS) compared to placebo-augmented behavior therapy. This highlights the exciting potential of combining DCS with behavior therapy to improve reductions in tic severity. However, prior to a large-scale clinical trial, it is essential to determine the feasibility and efficacy of augmenting behavior therapy with DCS over multiple treatment sessions. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04357951
Study type	Interventional
Source	Johns Hopkins University
Contact
Status	Withdrawn
Phase	Early Phase 1
Start date	April 15, 2023
Completion date	September 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04851678` - Longitudinal Impact of Stressors in Adults With Tourette Syndrome
Completed	`NCT02605902` - Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders	N/A
Completed	`NCT04007913` - Incorporating teleCBIT Into a Hospital-Based Tic Program	N/A
Completed	`NCT02900144` - Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)	N/A
Completed	`NCT02256475` - Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome	Phase 1
Completed	`NCT02216474` - Brain Stimulation in Movement Disorders	N/A
Completed	`NCT01329198` - Brain Stimulation for the Treatment of Tourette Syndrome	N/A
Terminated	`NCT00952601` - Pilot Study of the Modified Atkins Diet for Tourette Syndrome	Phase 1
Enrolling by invitation	`NCT00355927` - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.	N/A
Completed	`NCT00206323` - A Randomized, Placebo-controlled, Tourette Syndrome Study.	Phase 3
Completed	`NCT00004376` - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder	Phase 3
Completed	`NCT04498364` - Extinction Learning in Adults With Tourette Syndrome	N/A
Completed	`NCT00755339` - Role of the Sensory Experience in Generating Motor Tics in Tourette Syndrome
Completed	`NCT03325010` - Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome	Phase 2
Not yet recruiting	`NCT06081348` - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders	Phase 2
Completed	`NCT01702077` - Neurofeedback for Tourette Syndrome	N/A
Completed	`NCT01719523` - Open-Trial of EPI-743 for Adults With Tourette Syndrome	Phase 1
Completed	`NCT00231985` - Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder	Phase 2
Completed	`NCT00206336` - An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.	Phase 3
Terminated	`NCT03732534` - Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome	Phase 2